Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has provided an announcement.
QIAGEN has reported a manager transaction involving supervisory board member Metin Colpan following the company’s previously announced synthetic share repurchase and share consolidation program. Under the terms of this program, every 20 issued QIAGEN shares were consolidated into 19, resulting in Colpan’s holdings being reduced by 3,521 shares to a total of 66,877 common shares, in a non-quantifiable transaction executed outside a trading venue, highlighting the ongoing effects of the capital restructuring on insider share positions.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences and molecular diagnostics company whose shares are listed on multiple European exchanges as well as on the NYSE and Swiss markets. The company focuses on sample and assay technologies used in molecular testing across research, clinical diagnostics and pharmaceutical applications, serving laboratories and healthcare-related customers worldwide.
Average Trading Volume: 1,155,025
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.